Medicalgorithmics SA stock news
Medicalgorithmics SA has officially entered into business negotiations with a global, multi--billion--dollar MedTech company listed on the New York Stock Exchange (NYSE). The discussions, initiated following the execution of a mutual non--disclosure agreement (NDA), focus on the potential integration of Medicalgorithmics' proprietary AI--based technologies—specifically the DeepRhythmAI (DRAI) and DeepRhythm Platform (DRP)—into the partner's ambulatory cardiac diagnostic solutions. The scope of the potential collaboration includes both retrospective ECG analysis and Mobile Cardiac Telemetry (MCT) services for the U.S. and international markets.